AVI BioPharma And USAMRIID Announce NEUGENE Antisense Drug Demonstrates Efficacy Against Ebola Virus
AVI BioPharma, Inc. (Nasdaq:AVII), and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) today announced positive results from experiments testing the effect of AVI's NEUGENE(R) antisense drugs against Ebola virus (EBOV) in vivo. The NEUGENE compounds targeted several EBOV genes.